作者:Kaitlyn Corazzata、Peter J. Rose、Shunyan Mo、Joseph Snodgrass、Alexander Langston、Elaine C. Lee
DOI:10.1021/acs.oprd.1c00335
日期:2022.3.18
presence of alkyl sulfonates, which were identified as potential genotoxic impurities in our active pharmaceutical ingredient (API). As a result, we initiated a development effort to identify a method to remove the alkyl sulfonates that would be amenable for scale-up. Herein, we report our effort toward the development of a general approach using DABCO (1,4-diazabicyclo[2.2.2]octane) to remove alkyl sulfonates
在中期临床候选药物的路线开发过程中,我们面临存在烷基磺酸盐的挑战,烷基磺酸盐被确定为我们的活性药物成分 (API) 中潜在的基因毒性杂质。因此,我们开始了一项开发工作,以确定一种去除烷基磺酸盐的方法,该方法适合放大。在此,我们报告了我们为开发一种使用 DABCO(1,4-二氮杂双环[2.2.2]辛烷)去除烷基磺酸盐的通用方法所做的努力,该方法既高效又方便地从实验台进行放大。